Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response
#4131
Introduction: Neuroendocrine neoplasms (NENs) are associated with poor health-related quality of life (HRQOL) due to tumor and hormonal related symptoms and treatment-related toxicity. Peptide receptor radionuclide therapy (PRRT) delivers targeted therapy for tumor and hormonal control.
Aim(s): The changes in patient-reported global health status during PRRT was previously reported. Here we report changes in HRQOL by objective response status.
Materials and methods: A retrospective analysis of HRQOL and clinical data from 505 patients collected at 3 Australian and 1 Canadian site from May 2009 to December 2017. Eligible patients had progressive unresectable NENs and received 2-5 cycles of PRRT. HRQOL was assessed with EORTC QLQ-C30. Response was assessed by RECIST v1.1 based on end-of-treatment imaging. Patients were separated by objective response -Cohort 1: partial or complete response, Cohort 2: stable disease, Cohort 3: progressive disease. Overall HRQOL changes were presented descriptively.
Conference:
Presenting Author: Cehic G
Authors: Cehic G, Kong G, Corsini N, Chan D, Pavlakis N,
To read the full abstract, please log into your ENETS Member account.